Skip to Content

Clinical Trials

Last Updated: 10/06/2015

Leukemia Clinical Trials are Grouped by Disease Type:

Phase I Agents


Acute Lymphoblastic Leukemia (ALL)

Newly Diagnosed or Previously Treated 

Salvage Programs

Minimal Residual Diesease

Acute Myelogenous Leukemia (AML)

Newly Diagnosed

FLT3 Mutated Only

IDH Mutated only

Frontline AML Post-Hypomethylating Therapy for MDS

Secondary Leukemia

Mixed Phenotype Acute Leukemia

  • Clofarabine, Idarubicin, Cytarabine, Vincristine, and Corticosteroids (2013-0073)



Supportive Care for AML

Maintenance (Patients in CR)

Observational Studies

Myelodysplastic Syndrome (MDS) (Includes CMML)

Specific Situations

RAS Mutated

IDH 1/2 Mutations

Post Hypomethylating Agents:

Low Risk/IPSS Int-1

IPSS int-2 or high

MDS 20% Blasts

Chronic Lymphocytic Leukemia (CLL)

CLL Immunotherapy

Untreated - early stage

Untreated - all stages 

Mimimal Residual Disease

Prior Therapy

Richter’s Transformation   

  • Oral Selinexor (2014-0601)                        

Other Studies

Chronic Myelogenous Leukemia (CML)

Chronic phase

Accelerated Phase

Blastic Phase

Imatinib failures with T315l mutations (any stage)

Minimal Residual Disease

Treatment Discontinuation

Supportive Care

Other Studies

Roll-over Studies

Myeloproliferative Diseases



Hemophagocytic Lymphohistiocytosis

  • Alemtuzumab + Etoposide & Dexamethasone (2014-0989)

Leukemia Insights

Leukemia Insights is a quarterly newsletter for physicians and other health professionals. Insights has the latest leukemia news, research and results from ongoing clinical trials, and available leukemia programs at MD Anderson.

© 2015 The University of Texas MD Anderson Cancer Center